TELMISARTAN EFFECT VERSUS VALSARTAN EFFECT UPON THE REDUCTION OF MICROALBUMINURIA AT THE PATIENTS WITH METABOLIC SYNDROME.
MELINDA KOLCSÀR, GRIGORE DOGARU, CAMIL E. VARI, BIANCA TĂTAR, MARIA T. DOGARU
Download Full Article

Abstract:

Microalbuminuria (MIA), considered nowadays an important marker of insulin resistance syndrome can be influenced by a variety of antiangiotensinic drugs. We compared in 31 patients the antiproteinuric efficacy of two antiangiotensinic drugs: valsartan (80mg/day) and telmisartan (40mg/day). The duration of the study was 3 month, during which the metabolic, hemodynamic parameters and MIA were measured. Both valsartan and telmisartan reduced statistically significant the blood pressure and MIA, but there was no difference regarding the metabolic effects of the drugs. An important difference between the studied drugs was noticed in the high percentage of patients with normalbuminuria after telmisartan administration (40% versus 12.5%). Based on this data we concluded that the angiotensin-receptor-blocking agent with PPAR-gamma (peroxisome proliferator- activated receptor) agonist activity (telmisartan) has a beneficial effect in nephroprotection compared to a classical one (valsartan).

Top